Otsuka (OTCMKTS:OTSKY) Sets New 12-Month High – Here’s Why

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) hit a new 52-week high during mid-day trading on Thursday . The company traded as high as $37.52 and last traded at $37.52, with a volume of 181 shares. The stock had previously closed at $34.92.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on OTSKY. Zacks Research upgraded Otsuka from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 31st. UBS Group raised Otsuka to a “hold” rating in a report on Tuesday, January 27th. The Goldman Sachs Group lowered shares of Otsuka from a “strong-buy” rating to a “strong sell” rating in a research note on Friday, February 27th. Finally, Morgan Stanley raised shares of Otsuka to an “overweight” rating in a report on Friday, January 23rd. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold”.

Otsuka Stock Performance

The firm has a fifty day simple moving average of $34.24 and a 200-day simple moving average of $31.11. The company has a quick ratio of 1.67, a current ratio of 2.17 and a debt-to-equity ratio of 0.05. The company has a market cap of $38.86 billion and a PE ratio of 15.27.

Otsuka (OTCMKTS:OTSKY) last posted its earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.16. The business had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.78 billion. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. On average, research analysts forecast that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.86 EPS for the current fiscal year.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.